Point of Care Diagnostic Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Testing (Cardio-Metabolic Monitoring Kits, Infectious Disease Testing Kits, Glucose Monitoring Kits, Coagulation Monitoring Kits, Pregnancy and Fertility Testing Kits, Tumor/Cancer Markers, Urinalysis Testing Kits, Hematology Testing Kits, Others), By Platform (Lateral Flow Assay, Dipsticks, Micro Fluidics, Molecular Diagnostics, Others), By End-User (Diagnostic Centers, Research Laboratories, Home Care Settings, Others), By Mode (Prescription, OTC), And By Geography - Forecasts From 2022 To 2027

The Point of Care diagnostic market is projected to grow at a CAGR of 6.93% during the forecast period to reach US$44.384 billion in 2027 from US$27.762 billion in 2020.

The point-of-care diagnostics market is regarded as bedside testing which is known to be any form of diagnostic test that is performed in a laboratory. Point-of-care testing is done close to the patient but with the advent of modern medical advances, this type of testing has been made feasible to quickly and easily access a wide range of health factors to make the evaluation, diagnosis, prognosis, and screening as efficient as possible.

Point-of-care testing is essential in lowering the risk of potential errors which has resulted in the demand for point-of-care diagnosis increasing significantly both within and outside the hospital environment.  A few factors such as the increased availability of portable, hand-held, and transportable devices have significantly attributed to the shift of testing from hospitals to even at home, emergency care, and even inconvenience clinic.

The growing prevalence of cardiovascular diseases and even diabetes in a few emerging nations such as China and India have further resulted in an increase in the demand for point-of-care diagnostics.  For instance, according to the international diabetes federation in 2021, globally there were nearly 537 million adults belonging to the age group of 20 to 79 years living with diabetes globally.

Increasing prevalence of infectious and chronic diseases

Point-of-care tests have resulted in improving the management of infectious diseases, especially in developing regions but access to proper healthcare is a challenge. According to UNAIDS, around 20.6 million people in 2019 were living with HIV and 2.1 million people in India would be infected with HIV. Therefore, a high prevalence of HIV in the regions is likely to boost the demand for point-of-care diagnostics which is expected to accelerate the treatment of HIV infection

According to the World Health Organization, India accounts for the highest tuberculosis burden with an estimated incident of 2.64 million cases in 2020.  In the year 2020, an estimated 15,898 people in Brazil would regard it to be at a strong risk of zika virus infections down over 30,000 cases which were reported in 2019.

An Increase in the occurrence rate of disorders is yet another critical factor that is fueling the demand for the point-of-care diagnostics market. For instance, according to CDC, worldwide approximately four to five million children develop respiratory syncytial virus and lower respiratory tract infections at least once a year.

North America is estimated to grow significantly during the forecast period

North America is anticipated to grow significantly in the forecast period. An increase in the number of Covid-19 cases in the region is regarded to be a factor that is driving the growth of the point of care diagnostics market in the North American region.

Moreover, an increase in product innovations and the growth which can be seen in incidents of infectious and chronic disorders will also result in driving market growth in North America. USA and Canada are regarded to be key marketplaces responsible for regional market development.

Furthermore, this region has witnessed various governmental efforts leading to an increase in awareness about the early detection of regular health check-ups and diseases which is further leading to the promotion of point of care devices. Along with this, an increase in healthcare expenditures, a growth in the number of hospitals and even clinically diagnostic laboratories, and an increase in demand for collaborations among multiple players in the North American region is also expected to drive the market growth.

 Market Key Developments

• In January 2022, Roche launched its Cobas Pulse System in countries accepting the CE mark. This is Roche Diagnostics’ newest generation of connecting point-of-care solutions for professional blood glucose management.
• In October 2021, Thermo Fisher Scientific announced the receiving of an emergency use authorization from the FDA to run the COVID-19 tests from a new saliva sample collection method with the spectrum solutions spectrum DNA.
• In June 2021, BioMereux Announced a special Co exclusive distribution agreement with specific diagnostics for the specific reveal of a rapid AST system In Europe.

Point of Care Diagnostic Market Scope:

 

Report Metric	Details
Market Size Value in 2020	US$27.762 billion
Market Size Value in 2027	US$44.384 billion
Growth Rate	CAGR of 6.93% from 2020 to 2027
Base Year	2020
Forecast Period	2022–2027
Forecast Unit (Value)	USD Billion
Segments Covered	Testing, Platform, End User, Mode, And Geography
Regions Covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Companies Covered	Abbott Laboratories, Becton, Dickinson and Company, Chembio Diagnostic Systems, Danaher Corporation, EKF Diagnostics, Nova Biomedical, Quidel Corporation, Siemens AG, Trinity Biotech, WerfenLife S.A
Customization Scope	Free report customization with purchase

 

Segmentation:

• By Testing
  • Cardio-Metabolic Monitoring Kits
  • Infectious Disease Testing Kits
  • Glucose Monitoring Kits
  • Coagulation Monitoring Kits
  • Pregnancy and Fertility Testing Kits
  • Tumor/Cancer Markers
  • Urinalysis Testing Kits
  • Hematology Testing Kits
  • Others
• By Platform
  • Lateral Flow Assay
  • Dipsticks
  • Micro Fluidics
  • Molecular Diagnostics
  • Others
• By End User
  • Diagnostic Centers
  • Research Laboratories
  • Home Care Settings
  • Others
• By Mode
  • Prescription
  • OTC
• By Geography
  • North America
    • USA
    • Canada
    • Others
  • South America
    • Brazil
    • Others
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Israel
    • Others
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Thailand
    • Indonesia
    • Others

---

1. INTRODUCTION

1.1. Market Overview

1.2. COVID-19 Scenario

1.3. Market Definition

1.4. Market Segmentation

 

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

 

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

 

5. POINT OF CARE DIAGNOSTIC MARKET BY TESTING

5.1. Introduction

5.2. Cardio-Metabolic Monitoring Kits

5.3. Infectious Disease Testing Kits

5.4. Glucose Monitoring Kits

5.5. Coagulation Monitoring Kits

5.6. Pregnancy And Fertility Testing Kits

5.7. Tumor/Cancer Markers

5.8. Urinalysis Testing Kits

5.9. Hematology Testing Kits

5.10. Others

 

6. POINT OF CARE DIAGNOSTIC MARKET BY PLATFORM

6.1. Introduction

6.2. Lateral Flow Assay

6.3. Dipsticks

6.4. Micro Fluidics

6.5. Molecular Diagnostics

6.6. Others

 

7. POINT OF CARE DIAGNOSTIC MARKET BY MODE

7.1. Introduction

7.2. Prescription

7.3. OTC

 

8. POINT OF CARE DIAGNOSTIC MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. Germany

8.4.2. France

8.4.3. United Kingdom

8.4.4. Spain

8.4.5. Others

8.5. Middle East and Africa

8.5.1. Israel

8.5.2. Saudi Arabia

8.5.3. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. Japan

8.6.3. South Korea

8.6.4. India

8.6.5. Thailand

8.6.6. Indonesia

8.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Emerging Players and Market Lucrativeness

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

9.1. Abbott Laboratories

9.2. Becton, Dickinson and Company

9.3. Chembio Diagnostic Systems

9.4. Danaher Corporation

9.5. EKF Diagnostics

9.6. Nova Biomedical

9.7. Quidel Corporation

9.8. Siemens AG

9.9. Trinity Biotech

9.10. WerfenLife S.A

Abbott Laboratories

Becton, Dickinson and Company

Chembio Diagnostic Systems

Danaher Corporation

EKF Diagnostics

Nova Biomedical

Quidel Corporation

Siemens AG

Trinity Biotech

WerfenLife S.A